20161020 – Capital increase EN FINAL
Category: Press release
First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients
20161017-tg1050-md-us-final
Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study
alliance_transgene-collab-press-release_row
Transgene presents data on improved cytotoxic activity of oncolytic viruses expressing intrabodies in resistant tumor cell lines
20161005-ov-vancouver-vacv-antibody-poster-final-us
Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials
20160905 – H1 update – EN – V10
Transgene Announces Participation at Upcoming Investor Events
20160901 – Next investor events – EN
Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee
20160721 – Safety TG1050 EN Vdef
Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy
20160531 – ASCO_Poster_PR_V2_clean
Composition of the Board of Directors and Statutory Auditors
20160525 – nomination Mr Beret – us
Transgene Reports First Quarter 2016 Business Update
20160421 PR VEN Q1 2016 – V4 clean